Scientists have discovered a marker on leukemic stem cells and an antibody drug that binds to this marker is undergoing clinical trials in Australia and the US. ince the marker is specific for the cancer cells the treatment does not impact healthy cells – meaning that side effects may be limited, researchers said. The tumour marker is EphA3, and KB004, the antibody drug that binds to the marker, is undergoing clinical trials at several hospitals in Australia and in the US. One of the diseases being treated is AML (acute myeloid leukemia), one of the deadliest and hardest to treat …
Read More »